Apoptosis is directly related to intracellular amyloid accumulation in a cell line derived from the cerebral cortex of a trisomy 16 mouse, an animal model of Down syndrome.
Human Down syndrome (DS) represents the most frequent cause of mental retardation associated to a genetic condition. DS also exhibits a characteristic early onset of neuropathology indistinguishable from that observed in Alzheimer's disease (AD), namely the deposition of the beta-amyloid peptide. Early endosomal dysfunction has been described in individuals with DS and AD, suggesting an important role of this subcellular compartment in the onset and progression of the pathology. On the other hand, cholesterol activates the amyloidogenic processing pathway for the amyloid precursor protein, and the lipoprotein receptor-related peptide interacts with the beta-amyloid peptide. In the present work, using cell lines derived from the cortex of both normal and trisomy 16 mice (Ts16), an animal model of DS, we showed that the application of exogenous beta-amyloid has cytotoxic effects, expressed in decreased viability and increased apoptosis. Supplementation of the culture media with cholesterol associated to lipoprotein increased cell viability in both cell lines, but apoptosis decreased only in the normal cell line. Further, intracellular beta-amyloid content was elevated in trisomic cells following cholesterol treatment, with higher values in the trisomic cell line. Immunocytochemical detection showed intracellular accumulation of exogenous beta-amyloid in Rab4-positive compartments, which are known to be associated to endosomal recycling. The results suggest that the intracellular beta-amyloid pool plays a central role in apoptosis-mediated cell death in the trisomic condition.
Arriagada
Christian
C
ICBM, Program of Anatomy and Developmental Biology, Faculty of Medicine, University of Chile, Independencia 1027, Santiago, Chile. carriagada@med.uchile.cl
Bustamante
Miguel
M
Atwater
Illani
I
Rojas
Eduardo
E
Caviedes
Raúl
R
Caviedes
Pablo
P
D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D017209:Apoptosis / Q000502:physiology*; D002460:Cell Line; D002470:Cell Survival / Q000502:physiology; D002540:Cerebral Cortex / Q000503:physiopathology*; D002784:Cholesterol / Q000378:metabolism; D004195:Disease Models, Animal; D004314:Down Syndrome / Q000503:physiopathology*; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D042541:Intracellular Space / Q000378:metabolism*; D008074:Lipoproteins / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D010446:Peptide Fragments / Q000378:metabolism*; D014314:Trisomy
D016229:Amyloid beta-Peptides; D008074:Lipoproteins; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D002784:Cholesterol